Inclusion Criteria:

- Participated in the placebo arm of the SGN35-005 clinical study and experienced
disease progression of HL as defined by the SGN35-005 study protocol. Or in the US
only: Patients with relapsed or refractory HL or patients with relapsed or
refractory systemic ALCL who have previously failed frontline chemotherapy.

- Completed any previous treatment with radiation, chemotherapy, biologics and/or
investigational agents at least 4 weeks prior to the first dose of brentuximab
vedotin, unless underlying disease is progressing on therapy.

Exclusion Criteria:

- History of another primary malignancy that has not been in remission for at least 3
years

- Known cerebral/meningeal disease

- Peripheral neuropathy of grade 2 or greater

- Females who are pregnant or lactating

- Patients who are eligible to participate in other brentuximab vedotin clinical
studies